Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

People In Brief

This article was originally published in The Tan Sheet

Executive Summary

FDA appoints global, IT heads: The agency has chosen Lou Valdez as associate commissioner for international programs and Lori Davis as chief information officer. Valdez will lead the agency's further international expansion, with office openings planned for India, Latin America and the Middle East, FDA says Jan. 12. Melinda Plaisier stepped down as associate commissioner for international programs in October to become director of the Central region office in FDA's Office of Regulatory Affairs (1"The Tan Sheet" Dec. 8, 2008, p. 8). Davis has been deputy CIO since November 2007 and will now drive FDA's multi-year information technology modernization program, which will improve import and food protection by enhancing system interoperability

You may also be interested in...



Opening China Offices Brings FDA Early Test On Bridging Globalization Gaps

FDA's opening of offices in China will be an early test of how the agency handles the challenges of globalization, not only in working with foreign governments but also in restructuring itself to operate with worldwide footing

Sales & Earnings In Brief

Schering-Plough looks to emerging markets: As the U.S. economy continues to falter, Schering-Plough is increasingly focusing on emerging markets such as Brazil, China and Russia, CEO Fred Hassan says in an Oct. 21 third-quarter earnings release. He notes 70 percent of S-P's $4.6 billion in third-quarter net sales were outside the U.S. He adds, consumer and animal health account for approximately $758 million and $278 million of sales respectively. Laxative Miralax drove a 2 percent increase in OTC revenues with $31 million in sales - nearly double last year's third-quarter total. This was not enough to offset weak allergy sales with Claritin down 11 percent to $92 million. Other OTC sales slipped 11 percent to $37 million, contributing to a 1 percent fall of overall OTC sales to $160 million. Beyond OTCs, Kenilworth, N.J.-based S-P's net income fell 21 percent to $589 million in the third quarter

People In Brief

Poon leaving J&J: Johnson & Johnson has more than five months to choose the next global head of its Pharmaceuticals Group as Christine A. Poon announces she will retire in March 2009 after more than 23 years in the health care industry and eight years with the company. The firm says Poon, who also is vice chair of the board of directors, has not indicated whether she plans to continue working in the pharmaceutical industry. In an e-mail to company employees Poon said she will work with the firm "to successfully close 2008, complete plans for 2009 and provide assistance for an orderly transition." She added she has "a deep desire to take on new challenges and find opportunities to advance society and health through my continuing involvement with science, technology, innovation and business." Poon joined J&J in 2000 as group chairman for pharmaceuticals before being promoted to the executive committee and named worldwide chairman for pharmaceuticals in 2001 and worldwide chairman for medicines and nutritionals in 2003. She was elected to the board and named vice chair in 2005 and returned to the pharmaceutical post in 2007

Related Content

UsernamePublicRestriction

Register

PS102516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel